Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 2;11:932. doi: 10.3389/fneur.2020.00932

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Akaishi, Takeshita, Himori, Takahashi, Misu, Ogawa, Kaneko, Fujimori, Abe, Ishii, Fujihara, Aoki, Nakazawa and Nakashima.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Flow diagram of the subgroup classification according to the acute therapies. A total of 32 AQP4-IgG (+) patients with a first episode of optic neuritis (ON; 36 ON-involved eyes) were enrolled. Three patients were untreated, and the remaining 29 patients (32 ON-involved eyes) were initially treated with intravenous methylprednisolone pulse therapy. A total of 19 patients (21 ON-involved eyes) were further treated with adjunctive plasma exchange. AQP4-IgG, anti-aquaporin-4 autoantibodies; IVMP, intravenous methylprednisolone pulse therapy; ON, optic neuritis; PLEX, plasma exchange; VA, visual acuity.